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Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) is the causative agent of the ongoing COVID-19
pandemic. It is responsible for more than 1 million deaths
worldwide already [1]. Because preventive and anti-viral
treatment options are still limited, COVID-19 convalescent
plasma (CPP) has been suggested as a potential therapy
[2–4].
‘Convalescent’ implies that anti-SARS-CoV-2 antibod-
ies are present in plasma collected from individuals
recovered from COVID-19. However, the dose and nature
of antibodies required to effectively interfere with a
SARS-CoV-2 infection is unclear. Most ongoing observa-
tional studies and prospective clinical trials currently
focus on neutralizing antibodies (nAbs) that interfere with
viral binding to host cells, but non-neutralizing antibod-
ies might mediate a therapeutic effect as well. These and
other unknowns highlight the importance of testing CCP
efficacy in randomized trials. This commentary conse-
quently does not claim to provide evidence on how to
select potent CCP, but does want to provide an opinion-
based discussion on how to investigate CCP potency.
The antibody level in CCP varies greatly between
donors. Therefore, it is required to measure antibody titer
and/or to assess the neutralization potency of CCP. The
current gold standard for the latter is in vitro viral neu-
tralization like in the plaque reduction neutralization test
(PRNT) or microneutralization (MN) assay. Both measure
the ability of nAbs to prevent infection in vitro calculated
either as a reduction in the formation of plaques or as the
inhibition of viral infectivity in a cell monolayer,
respectively [5,6]. These assays utilize live SARS-CoV-2
virus and, hence, require a biosafety level 3 (BSL-3) facil-
ity. In addition, it is time-consuming (5–7 days). Further-
more, the output data cannot be compared among
laboratories because different assay readouts (e.g. virus
concentration or % inhibition) and protocols are currently
being used. In addition, an international standard is not
yet available. Blood establishments may choose to partner
with a virology laboratory that can perform viral neutral-
ization on donor samples. Alternatively, other assays are
available using pseudoviruses (i.e. a recombinant virus
expressing a SARS-CoV-2 protein) that require lower bio-
safety levels [7].
Anti-SARS-CoV-2 antibody titers can also be measured
using immunoassays such as enzyme-linked (ELISA) and
chemiluminescent immunoassays (CLIA) which are based
on biochemical detection of antibody binding to viral
proteins. Recently, the FDA suggested that all putative
CCP donations should be tested in the Ortho VITROS
SARS-CoV-2 IgG CLIA-based test and donations with a
signal to cut-off of 12 or higher to be qualified as a high
titer plasma [8]. In contrast, European blood establish-
ments are using a variety of commercial immunoassays
(Table 1), making it more difficult to compare data across
the region. Sensitivities and specificities of the commer-
cial assays presented in Table 1 can differ from those
provided by the respective manufacturers. Thresholds,
sensitivities and specificities may change depending on
sample size, the timing post-symptom onset and the sero-
prevalence in the population [9,10].
Immunoassays allow the detection of total or isotype-
specific antibody binding the spike (S), receptor binding
domain of spike (RBD) or nucleocapsid (N) proteins. In
our opinion, immunoassays for IgG targeting RBD are
most likely to be relevant because (i) most potent
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neutralizing antibodies are directed towards RBD, (ii)
IgG is efficiently transported across the epithelial lung
barrier [11] and (iii) IgG has a longer half-life. Finally,
immunoassays are compatible with BSL-1 facilities, do
not require sophisticated technology and may be emu-
lated on robots to increase throughput.
As viral neutralization assays are not high-throughput
and thus may become rate limiting for CCP release to
patients, immunoassays may be used to select CCP
donations. However, the immunoassay threshold that
selects a plasma product as CCP then ideally relates reli-
ably and reproducibly to a corresponding neutralization
titer. Recently, several research groups reported on this
correlation [12–15]. For example, Luchsinger et al. found
correlations between the Ortho IgG (r2 = 0.75), Abbott
IgG (r2 = 0.72) and an in-house IgG ELISA (r2 = 0.69)
with a pseudovirus neutralization assay [12]. Similar
results have been observed for the EUROimmun IgG
ELISA and a microneutralization or pseudotype assay
[13]. Another in-house RBD-based IgG ELISA correlated
well with virus neutralization (r2 = 0.89) [14]. Recently,
a correlation between anti-spike EUROimmun IgA and
virus neutralization (PRNT) was found, indicating that
also IgA might play a role in virus neutralization [15].
These efforts are at least suggestive for correlation
between certain immunoassays and viral neutralization.
The ELISA threshold and/or neutralization titer used
to distinguish CCP from non-CCP plasma remains an
arbitrary choice [16]. For viral neutralization, it ranges
from 1:40 to 1:320 while the FDA recommends 1:160,
but without an international standard these titers are not
comparable yet [8]. Note that the consequence of any
threshold for an immunoassay is a shift in the balance
bearing a risk of releasing poorly neutralizing CCP units
on the low end, and restricting release of potentially
neutralizing CCP on the high end (Fig. 1). In England,
neutralizing antibody titers of 1:100 or higher were
measured in 34% of donations, while using a higher
cut-off would likely have prevented a sufficient supply
of CCP to fulfill trial needs [17].
Of note, unbiased screening of all donors using
immunoassays without prior information on SARS-CoV-2
infection is not advised. As the actual number of seroposi-
tive individuals in the population is low, the positive pre-
dictive value (PPV) of any assay that is not 100% specific
will unavoidably cause overrepresentation of false posi-
tives [18]. Therefore, selection of CCP should be based on
laboratory confirmation of SARS-CoV-2 infection plus a
neutralization assay or a correlating immunoassay. Obser-
vational studies from Mayo clinic and Salazar et al
recently found that CCP is most effective when high
amounts of anti-SARS-CoV-2 IgG are present [4,19]. In
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no reduction in disease progression nor mortality [20] but
also did not determine nAbs levels upfront. Post hoc analy-
sis showed that the median titer of nAbs in this study was
low. Together with the scientific rationale of biochemical
interference with viral binding, we suggest that CCP selec-
tion is based on medium to high signal thresholds (i.e. the
top 30–40% of donations containing Abs). This selection
strategy may change in the future once the minimal effec-
tive dose of nAbs has been established and high-through-
put standardized assays that can reliably predict viral
neutralization potency are available.
As mentioned previously, standardization or calibration
of these immuno- and neutralization assays to allow
comparison of data across studies has not yet been per-
formed. In this context, the European Commission and
the European Blood Alliance (EBA) recently launched a
joint initiative to support high-quality clinical evaluation
of CCP. This SUPPORT-E consortium (Supporting high-
quality evaluation of COVID-19 convalescent plasma
throughout Europe) [21] will investigate the relationship
between (i) donor and donation parameters, (ii) antibody
content and nature and (iii) clinical outcome of CCP
recipients in EU cohorts. The consortium will also provide
support for testing and distributes calibration standards
among participating blood establishments in the EU to
allow cross border standardization of assays. In addition,
international standards are anticipated to be made avail-
able by the WHO in December 2020, which will facilitate
such direct comparisons [18].
Although the observational studies are suggestive for
CCP efficacy, hard evidence is lacking. Additional studies
are required, but IgG levels obtained by ELISA seem to
correlate well with virus neutralization titers. This indi-
cates that an ELISA/CLIA assay can be used to select CCP
donors, also in the light of the urgency. However, stan-
dardization of ELISAs will be essential.
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